Impact ledger
Moderna, Inc. (MRNA)
18 events mapped to this ticker since 2026-06-12.
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-16 | Event | Settlement payment of $178 million to Arbutus Biopharma represents a cash outflow, albeit already settled. The announcement serves as a reminder of past litigation costs. | Bearish | 1-3m | 0.20 |
| 2026-07-14 | Event | Indirect competitive pressure or validation of therapeutic approaches. While not directly competing in the same specific indications, advancements in novel drug classes can influence broader biotech investment trends. | watch | 3-12m | 0.20 |
| 2026-07-14 | Event | Valion Bio's expansion into oncology supportive care, while early, could eventually introduce a new competitor or technology in a space where Moderna also has interests (e.g., mRNA-based cancer therapies). The manufacturing scale-up also points to potential for broader biopharmaceutical production c | watch | 1-5y | 0.20 |
| 2026-07-13 | Event | Increased competition in the global vaccine market, particularly for emerging infectious diseases, potentially impacting future market share or pricing power for similar products. | watch | 1-5y | 0.30 |
| 2026-07-06 | Event | Increased M&A activity in oncology, particularly for novel mechanisms and early-stage assets, could signal a more favorable environment for biotech companies with strong pipelines, potentially increasing their strategic value or attracting similar acquisition interest. | watch | 1-3m | 0.30 |
| 2026-06-25 | Event | Increased M&A activity in the biotech sector, potentially leading to re-evaluation of similar-sized or strategically aligned companies. | watch | 1-3m | 0.40 |
| 2026-06-24 | Event | Increased investor scrutiny on biotechnology companies with significant R&D pipelines and limited commercial products, potentially impacting valuation multiples or access to capital. | watch | 1-3m | 0.20 |
| 2026-06-23 | Event | Increased competition in the I&I therapeutic area, potential for talent migration, and a benchmark for investor sentiment towards innovative biotech. | watch | 1-3m | 0.20 |
| 2026-06-23 | Event | Increased competition in drug development, particularly in areas where Odyssey Therapeutics may focus, could indirectly affect investor sentiment towards established biotech firms. | watch | 1-3m | 0.20 |
| 2026-06-22 | Event | Indirect sentiment spillover for gene therapy and neurological disorder treatments, potentially influencing investor appetite for the broader sector. | watch | 3-12m | 0.20 |
| 2026-06-17 | Event | General sentiment towards biotech sector, particularly companies with significant R&D pipelines. | watch | 3-12m | 0.10 |
| 2026-06-17 | Event | Regulatory approval process for new product, potential market expansion. | mixed | 1-3m | 0.80 |
| 2026-06-17 | Event | Indirectly, as a leader in mRNA technology, positive results from other mRNA-focused companies could bolster investor sentiment for the broader mRNA platform, though ELTX's platform is different. | watch | 3-12m | 0.20 |
| 2026-06-15 | Event | Indirect competitive pressure in the inflammatory bowel disease (IBD) market, as SPY002 could become a significant competitor to existing or pipeline IBD treatments. | watch | 1-3m | 0.30 |
| 2026-06-15 | Event | While not directly related, strong early-stage oncology data from a smaller biotech can sometimes signal broader positive sentiment for innovative oncology approaches, potentially benefiting other companies with diverse oncology pipelines or platform technologies, though the direct link is weak. | watch | 1-3m | 0.10 |
| 2026-06-15 | Event | Indirect competitive pressure. SPY002's success in ulcerative colitis could increase competition in the inflammatory bowel disease (IBD) market, potentially affecting future market share for existing or pipeline IBD treatments. | watch | 1-3m | 0.20 |
| 2026-06-12 | Event | Biotech sector is mentioned as sensitive to rate hike risks. Higher cost of capital impacts R&D-intensive companies with long development cycles. | Bearish | 3-12m | 0.60 |
| 2026-06-12 | Event | While not pre-revenue, biotech companies often have long development cycles and significant R&D expenses, making their future profitability sensitive to discount rates. Higher rates could also increase the cost of capital for future clinical trials or acquisitions. | Bearish | 3-12m | 0.60 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for MRNA, start a trial or view the MRNA entity page.